SMMT · Summit Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Mahkam Zanganeh Director | ▲ Buy | Open Market | 573,883,879 Shares held | 6/12/2026 | View profile |
| Robert W. Duggan Director | ▲ Buy | Open Market | 573,883,879 Shares held | 6/12/2026 | View profile |
| Yu Xia Director | ▲ Buy | Open Market | 32,057,147 Shares held | 10/21/2025 | View profile |
| Manmeet Singh Soni Chief Operating Officer | ▲ Buy | Open Market | 3,123,603 Shares held | 6/4/2026 | View profile |
| Ankur Dhingra Chief Financial Officer | ▲ Buy | Open Market | 354,958 Shares held | 3/26/2024 | View profile |
| Bhaskar Anand Chief Accounting Officer | ▲ Buy | Grant | 159,751 Shares held | 10/21/2025 | View profile |
| Huber Jeff Director | ▲ Buy | Grant | 44,052 Shares held | 9/11/2024 | View profile |
Transaction History
| Robert W. Duggan | ▲ Buy | Open Market | 3,810,000 | $50.0M | 6/12/2026 |
| Mahkam Zanganeh | ▲ Buy | Open Market | 3,810,000 | $50.0M | 6/12/2026 |
| Robert W. Duggan | ▲ Buy | Open Market | 100,000 | $1.5M | 6/4/2026 |
| Mahkam Zanganeh | ▲ Buy | Open Market | 100,000 | $1.5M | 6/4/2026 |
| Manmeet Singh Soni | ▲ Buy | Open Market | 25,000 | $362K | 6/4/2026 |
| Manmeet Singh Soni | ▲ Buy | Open Market | 25,000 | $361K | 6/4/2026 |
| Mahkam Zanganeh | ▲ Buy | Open Market | 26,680 | $500K | 10/21/2025 |
| Mahkam Zanganeh | ▲ Buy | Grant | 13,980,789 | $262.0M | 10/21/2025 |
| Yu Xia | ▲ Buy | Open Market | 533,617 | $10.0M | 10/21/2025 |
| Manmeet Singh Soni | ▲ Buy | Grant | 53,361 | $1000K | 10/21/2025 |
| Robert W. Duggan | ▲ Buy | Grant | 13,980,789 | $262.0M | 10/21/2025 |
| Robert W. Duggan | ▲ Buy | Grant | 266,808 | $5.0M | 10/21/2025 |
| Robert W. Duggan | ▲ Buy | Open Market | 26,680 | $500K | 10/21/2025 |
| Mahkam Zanganeh | ▲ Buy | Grant | 266,808 | $5.0M | 10/21/2025 |
| Bhaskar Anand | ▲ Buy | Grant | 26,680 | $500K | 10/21/2025 |
| Mahkam Zanganeh | ▲ Buy | Open Market | 5,000 | $90K | 9/11/2025 |
| Robert W. Duggan | ▲ Buy | Open Market | 5,000 | $90K | 9/11/2025 |
| Mahkam Zanganeh | ▲ Buy | Open Market | 333,394 | $5.9M | 9/10/2025 |
| Robert W. Duggan | ▲ Buy | Open Market | 333,394 | $5.9M | 9/10/2025 |
| Mahkam Zanganeh | ▲ Buy | Option Exercise | 74,545 | $197K | 5/30/2025 |
| Robert W. Duggan | ▲ Buy | Option Exercise | 74,545 | $197K | 5/30/2025 |
| Mahkam Zanganeh | ▼ Sell | Other | 3,985,055 | $6.3M | 4/8/2025 |
| Robert W. Duggan | ▼ Sell | Other | 3,985,055 | $6.3M | 4/8/2025 |
| Mahkam Zanganeh | ▼ Sell | Other | 315,681 | $499K | 10/3/2024 |
| Mahkam Zanganeh | ▲ Buy | Grant | 44,052 | $1000K | 9/11/2024 |
| Robert W. Duggan | ▲ Buy | Grant | 3,325,991 | $75.5M | 9/11/2024 |
| Huber Jeff | ▲ Buy | Grant | 44,052 | $1000K | 9/11/2024 |
| Manmeet Singh Soni | ▲ Buy | Grant | 44,052 | $1000K | 9/11/2024 |
| Bhaskar Anand | ▲ Buy | Grant | 22,026 | $500K | 9/11/2024 |
| Mahkam Zanganeh | ▲ Buy | Open Market | 20,000 | $74K | 3/27/2024 |
| Mahkam Zanganeh | ▲ Buy | Open Market | 34,321 | $128K | 3/27/2024 |
| Mahkam Zanganeh | ▲ Buy | Open Market | 26,000 | $97K | 3/27/2024 |
| Ankur Dhingra | ▲ Buy | Open Market | 100,000 | $375K | 3/26/2024 |
| Mahkam Zanganeh | ▲ Buy | Open Market | 30,000 | $113K | 3/26/2024 |
| Ankur Dhingra | ▲ Buy | Open Market | 700 | $2K | 12/13/2023 |
| Ankur Dhingra | ▲ Buy | Open Market | 19,700 | $43K | 12/13/2023 |
| Mahkam Zanganeh | ▲ Buy | Open Market | 5,000 | $10K | 12/12/2023 |
| Mahkam Zanganeh | ▼ Sell | Other | 315,681 | $499K | 12/11/2023 |
| Mahkam Zanganeh | ▼ Sell | Other | 489,814 | $705K | 12/11/2023 |
| Manmeet Singh Soni | ▲ Buy | Open Market | 2,976,190 | $5.0M | 10/13/2023 |
| Mahkam Zanganeh | ▲ Buy | Open Market | 15,973,743 | $16.8M | 3/8/2023 |
| Mahkam Zanganeh | ▲ Buy | Open Market | 804,672 | $845K | 3/8/2023 |
| Mahkam Zanganeh | ▲ Buy | Open Market | 6,748,629 | $7.1M | 3/8/2023 |
| Ankur Dhingra | ▲ Buy | Open Market | 196,362 | $206K | 3/7/2023 |
| Robert W. Duggan | ▲ Buy | Open Market | 376,489,880 | $395.3M | 3/6/2023 |
| Robert W. Duggan | ▼ Sell | Other | 9,346,434 | — | 12/6/2022 |
| Mahkam Zanganeh | ▼ Sell | Other | 373,857 | — | 12/6/2022 |
| Mahkam Zanganeh | ▲ Buy | Open Market | 1,030,925 | $1000K | 8/16/2022 |
| Ankur Dhingra | ▲ Buy | Open Market | 24,658 | $24K | 8/16/2022 |
| Mahkam Zanganeh | ▲ Buy | Open Market | 184,430 | $179K | 8/16/2022 |
| Robert W. Duggan | ▲ Buy | Open Market | 94,849,203 | $92.0M | 8/16/2022 |
| Ankur Dhingra | ▲ Buy | Open Market | 11,557 | $11K | 8/16/2022 |
| Mahkam Zanganeh | ▲ Buy | Open Market | 4,593,777 | $4.5M | 8/16/2022 |
| Robert W. Duggan | ▼ Sell | Other | 21,135 | — | 5/23/2022 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Summit Therapeutics Partners With AstraZeneca and Daiichi Sankyo
Summit Therapeutics announced a new collaboration with AstraZeneca and Daiichi Sankyo to test a cancer therapy combination. This partnership involves an ADC-bispecific approach and was described by the CEO as an important expansion of the company’s work. The stock rose 7.3% following the news, reflecting investor interest in this strategic alliance.
Summit Therapeutics Partners With AstraZeneca and Daiichi Sankyo. Summit Therapeutics announced a new collaboration with AstraZeneca and Daiichi Sankyo to test a cancer therapy combination. This partnership involves an ADC-bispecific approach and was described by the CEO as an important expansion of the company’s work. The stock rose 7.3% following the news, reflecting investor interest in this strategic alliance.